Delivery Order SPE2DB22D3011-SPE2DB25FQ2KN
- Not listed
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $1,790.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a competitive award with no set-aside designation. The award was fulfilled by AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania, the...
- The Defense Logistics Agency awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 15, 2025, and represents a non-set-aside procurement. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this medical supply delivery. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $17,908 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product. This firm fixed-price, non-set-aside delivery order was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,895.79 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-competed, firm fixed-price delivery order has a completion date of August 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial, a rabies immunoglobulin product, with performance in Conshohocken, Pennsylvania. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $8,954.05 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML, a rabies immunoglobulin product. This firm fixed-price delivery order, issued on August 29, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- This delivery order, awarded August 14, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of HYPERRAB 300 unit/mL vials (5 mL), a rabies immunoglobulin product critical for post-exposure prophylaxis in military and federal healthcare settings. The contract is valued at $1,790.80 with a firm fixed price structure and an ultimate completion date of September 5, 2025. The award was made through competitive procurement with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order valued at $10,744.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immune globulin product. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and represents a direct procurement of critical immunological...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2KNDelivery Order
The Defense Logistics Agency awarded a $21,489.60 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. The contract, issued on August 25, 2025, with an ultimate completion date of September 16, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania. This award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) designated SPE2DX with the DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has demonstrated significant capability in fulfilling federal medical procurement requirements through multiple competitively awarded contracts with the Defense Logistics Agency. The company's extensive portfolio includes brand-name and generic medications, vaccines, specialty pharmaceuticals, and medical supplies supporting military and veteran healthcare systems. This delivery order reflects the contractor's continued role as a critical vendor within the DLA's pharmaceutical supply chain, enabling the provision of essential medical commodities to support military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.5k | 8/25/25 |